Ad
related to: cafepharma company boards regeneron treatment program- Antibodies at Work
End-to-End Research & Development
See Regeneron's Approved Medicines
- Science & Technology
See Regeneron's New Technology
Turning Science into Medicine
- About Regeneron
Industry-Leading Biotechnology
Reinventing Drug Discovery
- Genetic Research
Speeding Drug Discovery
Learn about the RGC
- Antibodies at Work
Search results
Results From The WOW.Com Content Network
"Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs. U.S. sales ...
A potential treatment against the COVID-19 virus could be coming, but not in the form of another vaccine. Healthcare company Regeneron is seeking approval from the U.S. Food and Drug Administration...
George D. Yancopoulos (born 1959) is a Greek - American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals. [1] Yancopoulos is the holder of more than 100 patents. [2] He is a principal inventor and developer of Regeneron's ten FDA -approved or -authorized treatments, as well as of ...
Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a billionaire. In 2014 Eylea grossed $1.735 billion.
About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and ...
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo
Ad
related to: cafepharma company boards regeneron treatment program